Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein

• Rachel NeMoyer,
• Arindam Mondal,
• Mehul Vora,
• Elaine Langenfeld,
• Danea Glover,
• Michael Scott,
• Lauren Lairson,
• Christopher Rongo,
• David J. Augeri,
• Youyi Peng,
• Salma K. Jabbour,
• John Langenfeld

Affiliations

Rachel NeMoyer

Department of Surgery, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey

Arindam Mondal

Department of Surgery, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey

Mehul Vora

Department of Genetics, Rutgers University

Elaine Langenfeld

Department of Surgery, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey

Danea Glover

RBHS Rutgers Biomedical and Health Sciences, Rutgers University

Michael Scott

Department of Surgery, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey

Lauren Lairson

Rutgers University

Christopher Rongo

Department of Genetics, Rutgers University

David J. Augeri

Ernest Mario School of Pharmacy, Rutgers Translational Science, Rutgers University

Youyi Peng

Biomedical Informatics Shared Resources, Rutgers Cancer Institute of New Jersey

Salma K. Jabbour

Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School

John Langenfeld

Department of Surgery, Rutgers Robert Wood Johnson Medical School, The State University of New Jersey